Retatrutide

Retatrutide represents the next leap in obesity medicine as a Triple Hormone Receptor Agonist (GIP/GLP-1/Glucagon). Phase 2 clinical data revealed distinct advantages over dual agonists: by activating the glucagon receptor, Retatrutide increases energy expenditure (thermogenesis) and promotes robust lipid oxidation, countering the metabolic slowdown typically seen during rapid weight loss. Trials demonstrated weight reductions of up to 24.2% in 48 weeks, with efficacy continuing to climb without a clear plateau. Uniquely, it has shown extraordinary potency in reversing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), with imaging studies reporting >80% reduction in liver fat content, effectively 'de-fatting' the liver. This triple mechanism offers a comprehensive metabolic reset, simultaneously addressing severe obesity, insulin resistance (HOMA2-IR reduction), and lipid pathology.